查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1628124

心臟閉合裝置市場機會、成長促進因素、產業趨勢分析與預測 2025 - 2034 年

Heart Closure Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球心臟閉合裝置市場到2024 年價值40 億美元，預計2025 年至2034 年將以15.9% 的複合年成長率強勁成長。的轉變，以及改善報銷政策等因素。

心血管疾病（CVD）仍然是全球主要的健康問題，每年導致數百萬人死亡。人口老化、生活方式相關風​​險因素的增加以及久坐的生活方式推動了對心臟閉合裝置的需求。這些設備對於有效治療心臟缺陷變得至關重要，並且由於其微創性質而被視為許多患者的理想解決方案。

心臟閉合裝置的需求因其提供傳統手術侵入性較小的替代方案的能力而受到推動。這些裝置通常透過基於導管的手術插入，與傳統的心臟直視手術相比，患者可以更快地康復，疼痛更少，住院時間更少。隨著患者和醫療保健提供者擴大選擇微創治療，心臟閉合裝置市場正在穩步成長。

市場範圍
開始年份 2024年
預測年份 2025-2034
起始值 40 億美元
預測值 177 億美元
複合年成長率 15.9%

心臟閉合裝置用於閉合異常的心臟開口，特別是房間隔缺損和室間隔缺損，這是先天性疾病。這些缺陷會導致心室之間出現意外的血流。從產品類型來看，市場分為左心耳（LAA）封堵器、房間隔缺損（ASD）封堵器、室間隔缺損（VSD）封堵器、卵圓孔未閉（PFO）封堵器等類別，LAA 設備因其眾多優勢而引領市場。

左心耳封堵器在降低中風風險方面特別有效，並提供了長期抗凝血治療的替代方案，長期抗凝血治療可能會導致併發症。這些設備因其低併發症率、更快的恢復速度和更少的住院時間而越來越受到青睞，從而導致更高的採用率。科技的進步和意識的提高也推動了左心耳設備的使用不斷增加。

在材料方面，基於鎳鈦諾的心臟閉合裝置由於其超彈性和優異的生物相容性預計將引領市場成長。這些裝置被壓縮到導管中，用於微創手術，並且在心臟內的動態力下表現良好，確保患者的長期安全。對可靠心血管解決方案不斷成長的需求正在推動對這些設備的需求，預計到 2034 年市場規模將超過 92 億美元。

經導管輸送方法比傳統手術侵入性更小，是心臟閉合裝置市場的另一個關鍵成長動力。透過經導管手術，患者的併發症更少，恢復時間更快，使其成為醫療保健提供者和患者的普遍選擇。隨著經導管技術的不斷改進，這些設備的市場佔有率預計將大幅成長。

就最終用途而言，醫院憑藉其先進的設施和處理複雜心臟閉合手術的專業知識而佔據市場主導地位。熟練的醫療專業人員的存在確保患者獲得最高標準的護理，進一步鞏固醫院的市場領導地位。

北美引領全球心臟閉合設備市場，預計2025 年至2034 年複合年成長率為14.3%。領域的主導地位設備市場。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 心血管疾病盛行率不斷上升
      • 技術進步
      • 對微創手術的偏好不斷上升
      • 優惠報銷政策
    • 產業陷阱與挑戰
      • 嚴格的監理政策
      • 潛在的併發症和不良事件
  • 成長潛力分析
  • 監管環境
  • 報銷場景
  • 2023 年定價分析
  • 技術景觀
  • 未來市場趨勢
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2034 年

  • 主要趨勢
  • 心房中隔缺損 (ASD) 封堵器
  • 室間隔缺損 (VSD) 封堵器
  • 卵圓孔未閉 (PFO) 閉合裝置
  • 左心耳 (LAA) 封堵器
  • 其他產品

第 6 章：市場估計與預測：按材料分類，2021 - 2034 年

  • 主要趨勢
  • 基於鎳鈦諾的設備
  • 不銹鋼裝置
  • 其他材料

第 7 章：市場估計與預測：按交付方式，2021 年至 2034 年

  • 主要趨勢
  • 經導管輸送
  • 手術分娩

第 8 章：市場估計與預測：按最終用途，2021 - 2034 年

  • 主要趨勢
  • 醫院
  • 門診手術中心 (ASC)
  • 心導管實驗室
  • 其他最終用途

第 9 章：市場估計與預測：按地區分類，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • Abbott Laboratories
  • AtriCure
  • Biosense Webster
  • Boston Scientific Corporation
  • Cardia
  • Heartstitch
  • Lepu Medical Technology (Beijing)Co., Ltd.
  • LifeTech Scientific Corporation
  • Medtronic
  • Occlutech
  • SentreHEART
  • Starway Medical Technology
  • WL Gore & Associates
簡介目錄
Product Code: 6140

The Global Heart Closure Devices Market, valued at USD 4 billion in 2024, is expected to grow at a robust CAGR of 15.9% from 2025 to 2034. This growth can be attributed to the rising prevalence of cardiovascular diseases, a shift towards minimally invasive procedures, and improved reimbursement policies, among other factors.

Cardiovascular diseases (CVDs) remain a leading global health issue, contributing to millions of deaths annually. The aging population, increasing lifestyle-related risk factors, and sedentary living have propelled the demand for heart closure devices. These devices are becoming essential in treating heart defects effectively and are seen as an ideal solution for many patients due to their minimally invasive nature.

The demand for heart closure devices is fueled by their ability to offer a less invasive alternative to traditional surgeries. These devices are typically inserted via catheter-based procedures and allow patients to recover faster with less pain and fewer hospital stays compared to conventional open-heart surgeries. As patients and healthcare providers increasingly opt for minimally invasive treatments, the heart closure devices market is growing steadily.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$4 Billion
Forecast Value$17.7 Billion
CAGR15.9%

Heart closure devices are used to close abnormal heart openings, particularly atrial and ventricular septal defects, which are congenital conditions. These defects cause unintended blood flow between the heart's chambers. In terms of product type, the market is divided into categories such as left atrial appendage (LAA) closure devices, atrial septal defect (ASD) closure devices, ventricular septal defect (VSD) closure devices, and patent foramen ovale (PFO) closure devices, with LAA devices leading the market due to their numerous benefits.

LAA closure devices are particularly effective in reducing stroke risk and offer an alternative to long-term anticoagulant therapy, which can cause complications. These devices are increasingly preferred for their low complication rates, faster recovery, and reduced hospital stays, leading to a higher adoption rate. Technological advances and increased awareness are also driving the growing use of LAA devices.

In terms of material, nitinol-based heart closure devices are expected to lead market growth, owing to their superelasticity and excellent biocompatibility. These devices are compressed into catheters for less invasive procedures and perform well under the dynamic forces within the heart, ensuring long-term patient safety. The growing need for reliable cardiovascular solutions is driving the demand for these devices, with the market projected to reach over USD 9.2 billion by 2034.

The transcatheter delivery method, which is less invasive than traditional surgery, is another key growth driver in the heart closure devices market. With transcatheter procedures, patients experience fewer complications and a faster recovery time, making it a popular choice among both healthcare providers and patients. As transcatheter technologies continue to improve, the market share for these devices is expected to grow significantly.

In terms of end-use, hospitals dominate the market due to their advanced facilities and expertise in handling complex heart closure procedures. The presence of skilled medical professionals ensures that patients receive the highest standard of care, further reinforcing hospitals' market leadership.

North America leads the global market for heart closure devices, with a projected CAGR of 14.3% from 2025 to 2034. The region's early adoption of innovative technologies, coupled with favorable reimbursement policies and substantial investments in research, further supports its dominance in the heart closure devices market.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of cardiovascular diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising preference for minimally invasive procedures
      • 3.2.1.4 Favorable reimbursement policies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Potential complications and adverse events
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Pricing analysis, 2023
  • 3.7 Technology landscape
  • 3.8 Future market trends
  • 3.9 Gap analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn, Units)

  • 5.1 Key trends
  • 5.2 Atrial Septal Defect (ASD) Closure devices
  • 5.3 Ventricular Septal Defect (VSD) Closure devices
  • 5.4 Patent Foramen Ovale (PFO) Closure devices
  • 5.5 Left Atrial Appendage (LAA) Closure devices
  • 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Nitinol-based devices
  • 6.3 Stainless steel devices
  • 6.4 Other materials

Chapter 7 Market Estimates and Forecast, By Mode of Delivery, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Transcatheter delivery
  • 7.3 Surgical delivery

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers (ASCs)
  • 8.4 Cardiac catheterization laboratories
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn, Units)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AtriCure
  • 10.3 Biosense Webster
  • 10.4 Boston Scientific Corporation
  • 10.5 Cardia
  • 10.6 Heartstitch
  • 10.7 Lepu Medical Technology (Beijing)Co., Ltd.
  • 10.8 LifeTech Scientific Corporation
  • 10.9 Medtronic
  • 10.10 Occlutech
  • 10.11 SentreHEART
  • 10.12 Starway Medical Technology
  • 10.13 W. L. Gore & Associates